NXTMH logo

Nexstim Plc Stock Price

HLSE:NXTMH Community·€64.2m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author

NXTMH Share Price Performance

€8.90
0.46 (5.45%)
€12.50
Fair Value
€8.90
0.46 (5.45%)
28.8% undervalued intrinsic discount
€12.50
Fair Value
Price €8.90
AnalystConsensusTarget €12.50

NXTMH Community Narratives

AnalystConsensusTarget·
Fair Value €12.5 28.8% undervalued intrinsic discount

Brain Disease Tailwinds Will Ultimately Fail To Offset Mounting Business And Partnership Risks

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
€12.5
28.8% undervalued intrinsic discount
Profit Margin
25.92%
Future PE
15.2x
Price in 2028
€15.1

Trending Discussion

Updated Narratives

NXTMH logo

Brain Disease Tailwinds Will Ultimately Fail To Offset Mounting Business And Partnership Risks

Fair Value: €12.5 28.8% undervalued intrinsic discount
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with high growth potential.

2 Risks
3 Rewards

Nexstim Plc Key Details

€12.4m

Revenue

€2.5m

Cost of Revenue

€9.9m

Gross Profit

€9.3m

Other Expenses

€573.2k

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 14, 2026
0.079
79.78%
4.62%
98.8%
View Full Analysis

About NXTMH

Founded
2000
Employees
40
CEO
Mikko Karvinen
WebsiteView website
www.nexstim.com

Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company offers non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS), including Navigated Brain Stimulation (NBS) system 6 for presurgical mapping of the speech and motor cortices of the brain, for the treatment of major depression and chronic unilateral neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb. The company markets and sells its diagnostics systems to universities and teaching hospitals. It has an exclusive collaboration with Sinaptica Therapeutics, Inc. for the development, manufacture, and delivery of precision neuromodulation system for the treatment of Alzheimer’s disease and mild cognitive impairment; and a development and distribution collaboration with Brainlab AG for motor and speech mapping systems. The company was incorporated in 2000 and is headquartered in Helsinki, Finland.

Recent NXTMH News & Updates

Recent updates

No updates